Wyeth taps Cost to head corporate affairs dept.

Share this article:

Wyeth hired Timothy Cost to head its corporate affairs department, replacing Marily Rhudy, who is retiring.

Cost joins the company from Philadelphia food services firm Aramark, where he was EVP, corporate affairs. He becomes senior vice president, corporate affairs, reporting to president and CEO Bernard Poussot. 

Prior to joining Aramark in 2003, he had spent many years in the pharmaceutical industry, serving as SVP, communications and strategy for Centocor, VP, investor relations and corporate intelligence for Bristol-Myers Squibb and SVP, corporate affairs for Pharmacia. Poussot said in a statement: “His extensive and broad experience, especially in the biotechnology and pharmaceutical sectors, will help us as we continue to deliver innovative new products and navigate the changing business environment.”

Rhudy joined Wyeth in 1993 as assistant VP, professional relations for pharmaceuticals and worked her way up while building the public affairs function, rising to SVP, corporate public affairs in 2004.

She had previously served on the White House Health Care Professionals Task Force on Health Care Reform.

Poussot credited Rhudy with having “built an outstanding public affairs team that has forged strong external relationships to raise the level of awareness of Wyeth's contributions to healthcare.” 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...